Ronald Pyram
Endocrinology, Diabetes & Metabolism · East Stroudsburg, PANPI 1720241284
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,280 of the $11,926 with a category attached, or 61.0%. Merck accounts for 66.8% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $9,641 and has fallen 95.7% since, to $418 in 2025.
Across 144 payments — averaging $82.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$8K
- AstraZeneca$758
- Novo Nordisk$652
- Sanofi-aventis U.S. LLC$425
- Xeris Pharmaceuticals, Inc.$402
- Medtronic$339
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$7,28061%
- Travel & lodging$2502%
- Food & beverage$4,39037%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 19 | $7,966 |
| AstraZeneca | 31 | $758 |
| Novo Nordisk | 20 | $652 |
| Sanofi-aventis U.S. LLC | 21 | $425 |
| Xeris Pharmaceuticals, Inc. | 7 | $402 |
| Medtronic(2 entities) | 7 | $339 |
| Boehringer Ingelheim | 11 | $316 |
| OPKO Pharmaceuticals, LLC | 2 | $223 |
| Mannkind Corporation | 1 | $125 |
| Esperion Therapeutics, Inc. | 1 | $124 |
| Bayer | 1 | $117 |
| Tandem Diabetes Care, Inc. | 3 | $107 |
| Amgen | 5 | $91 |
| Johnson & Johnson | 4 | $67 |
| Shire North American Group Inc | 3 | $55 |
| Insulet Corporation | 2 | $44 |
| Eisai Inc. | 1 | $24 |
| Gilead | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Abbott | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,926 in reported general payments places this provider in the 80th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 11 | $13,244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $16 | $13,24411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in East Stroudsburg
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Geraldo SaavedraWhitehall$698K
- Jane MayrinPhiladelphia$628K
- Stephan KowalykGreensburg$591K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
- James DickeHanover$425K
- Mitchell LazarPhiladelphia$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.